יום רביעי, כ״ז אלול תשפ״וWednesday, September 9, 2026
Follow Us
The Novartis dug company is in advanced talks to buy up Israeli-based stem cell treatments developer Gamida-Cell for $600 million, sources told the Globes business newspaper. Slightly more than half of Gamida-Cell is owned by Clal Biotechnology and Elbit Medical Technologies, a subsidiary of Elbit Imaging. Gamida-Cell has been considering offering an IPO on Wall […]
September 4, 2026 
